Exclusive Summary

• Tenofovir disoproxil fumarate is post-patent cliff, with a mature global generic market and clear demand.
• The enormous patient populations for HBV and HIV, along with WHO's essential medicine listing, ensure robust and long-term market demand.
• The product offers clear cost advantages and potential quality/compliance benefits, making it attractive for global distribution, especially in low- and middle-income countries.
• As a well-established generic, its sales success depends on efficient distribution networks and inclusion in government/insurance procurement lists.